A Prospective, Multicenter, Single Arm, Open Label, Phase IIa Study to Assess the Safety and Efficacy of Once-a-month Long-acting Intramuscular Injection of 40mg Glatiramer Acetate (GA Depot) in Subjects With Primary Progressive Multiple Sclerosis (PPMS)

Next Previous
Trial Profile

A Prospective, Multicenter, Single Arm, Open Label, Phase IIa Study to Assess the Safety and Efficacy of Once-a-month Long-acting Intramuscular Injection of 40mg Glatiramer Acetate (GA Depot) in Subjects With Primary Progressive Multiple Sclerosis (PPMS)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Jan 2018

At a glance

  • Drugs Glatiramer acetate (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Sponsors Mapi Pharma

    • Most Recent Events

    • 30 Jan 2018 According to a Mapi Pharma media release, patients are currently being recruited at the Tel Aviv Sourasky Medical Center (Ichilov), The Barzilai Medical Center and Assaf Harofeh Medical Center.
    • 30 Jan 2018 According to a Mapi Pharma media release, first patient has been treated.
    • 30 Jan 2018 Status changed from not yet recruiting to recruiting, according to a Mapi Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top